Carnitine palmitoyltransferase 1C promotes EMT-associated cisplatin resistance in non-small cell lung cancer cells
These data provide evidence for the first time that the lipid metabolism enzyme, CPT1C, mediates resistance to chemotherapy. Therefore, the use of combination therapy with a CPT1C inhibitor may be a promising new avenue in lung cancer treatment.
Authors
- Huijun Wei (ORCID: https://orcid.org/0000-0003-1961-614X)
- Yitao Hu (ORCID: https://orcid.org/0009-0002-0231-4575)
- Xuefeng Hu (ORCID: https://orcid.org/0000-0001-9683-3506)
- Jiahui Wang (ORCID: https://orcid.org/0000-0002-4855-5094)
- Shanshan Huang (ORCID: https://orcid.org/0000-0003-1394-3481)
- Tiange Zhang (ORCID: https://orcid.org/0000-0003-0760-9380)
- Renjie Chen (ORCID: https://orcid.org/0000-0002-9448-0820)
- Zhihao Wu (ORCID: https://orcid.org/0000-0001-8368-5129)
- Yushu Huang (ORCID: https://orcid.org/0000-0002-0504-0234)
- Sihui Nian
- Xinran He
Institutions
- Wannan Medical College (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-02-04
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2024.0459
- Citations
- 8
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 7.49
Funders
- National Natural Science Foundation of China
- Wannan Medical College
- State Key Laboratory of Molecular Oncology